KHADIJA HAMISI: Open Payments
NPI 1225360498 · RIVERSIDE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,755 in 86 payments from 9 companies in 2025. Trend: 2023 $1,952 · 2024 $2,488 · 2025 $2,755
Food & beverage: $1,556Consulting: $1,088Education: $111
| Company | Payments | Amount |
|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $1,088 |
| Alkermes, Inc. | 29 | $467 |
| Bausch Health US, LLC | 16 | $349 |
| Teva Pharmaceuticals USA, Inc. | 11 | $275 |
| ABBVIE INC. | 8 | $182 |
| Otsuka America Pharmaceutical, Inc. | 9 | $181 |
| E.R. Squibb & Sons, L.L.C. | 9 | $165 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $32 |
| Janssen Pharmaceuticals, Inc | 1 | $18 |
Products named: ABILIFY ASIMTUFII, ARISTADA, APLENZIN, VRAYLAR, COBENFY, UZEDY, ABILIFY MAINTENA, AUSTEDO XR.
Industry payments across CA — which companies pay providers there.
